Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study — Efstathios Kastritis (2015) | RDL Network
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study
Letter 2015 en
Authors
EK
Efstathios Kastritis
MG
Maria Gavriatopoulou
MK
Marie‐Christine Kyrtsonis
Abstract
1 min read
Figure 2. Outcomes of patients who participated in the phase 2 study of the combination of DRC in previously untreated patients with symptomatic WM. PD, progressive disease; SD, stable disease.
Discussion(0)
No comments yet. Be the first to comment.